Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: Influence of different therapies

Stroke

Volumn 34, Issue 9, 2003, Pages 2165-2170

  Horstmann, Solveig ^a   Kalb, Pamela ^a   Koziol, James ^b   Gardner, Humphrey ^c   Wagner, Simone ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c BIOGEN   (United States)

Author keywords

Hypothermia; Metalloproteinases; Stroke, ischemic; Thrombolytic therapy

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; HEPARIN; LAMININ; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; FIBRINOLYTIC THERAPY; HEPARINIZATION; HUMAN; INDUCED HYPOTHERMIA; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STROKE;

ADULT; AGED; BRAIN ISCHEMIA; CEREBRAL INFARCTION; CEREBROVASCULAR ACCIDENT; COLLAGENASES; DISEASE PROGRESSION; FEMALE; HEPARIN; HUMANS; HYPOTHERMIA, INDUCED; LAMININ; MALE; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MIDDLE AGED; REFERENCE VALUES; THROMBOLYTIC THERAPY; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0041829250     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000088062.86084.F2     Document Type: Article

References (38)

1. Woessner JFJ, Nagase H. Introduction to the Matrix Metalloproteinases (MMPs). New York, NY: Oxford University Press; 2000:1-10.
2. Bode W, Fernandez-Catalan C, Grams F, Gomis-Ruth FX, Nagase H, Tschesche H, Maskos K. Insights into MMP-TIMP interactions. Ann N Y Acad Sci. 1999;878:73-91.
3. Rosenberg GA, Estrada EY, Dencoff JE. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke. 1998;29:2189-2195.
4. Hamann GF, Okada Y, del Zoppo GJ. Hemorrhagic transformation and microvascular integrity during focal cerebral ischemia/reperfusion. J Cereb Blood Flow Metab. 1996;16:1373-1378.
5. Hamann GF, Okada Y, Fitridge R, del Zoppo GJ. Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke. 1995;26:2120-2126.
6. Clark AW, Krekoski CA, Bou SS, Chapman KR, Edwards DR. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett. 1997;238:53-56.
7. Montaner J, Alvarez-Sabin J, Molina CA, Angles A, Abilleiri S, Arenillas J, Monasterio J. Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke. 2001;32:2762-2767.
8. Montaner J, Alvarez-Sabin J, Molina C, Angles A, Abilleira S, Arenillas J, Gonzalez MA, Monasterio J. Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke. 2001;32:1759-1766.
9. Hacke W, Brott T, Caplan L, Meier D, Fieschi C, von Kummer R, Donnan G, Heiss WD, Wahlgren NG, Spranger M, et al. Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology. 1999;53(suppl 4):S3-14.
10. Hacke W, Ringleb P, Stingele R. Thrombolysis in acute cerebrovascular disease: indications and limitations. Thromb Haemost. 1999;82:983-986.
11. Woessner JFJ, Nagase H. Activation of zymogen forms of MMPs. In: Matrix Metalloproteinases and TIMPs. New York, NY: Oxford University Press; 2000:72-86.
12. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana M, Alvarez-Sabin J. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003;107:598-603.
13. Schwab S, Schwarz S, Spranger M, Keller E, Bertram M, Hacke W. Moderate hypothermia in the treatment of patients with severe middle cerebral artery infarction. Stroke. 1998;29:2461-2466.
14. Wagner S, Gardner H. Modes of regulation of laminin-5 production by rat astrocytes. Neurosci Lett. 2000;284:105-108.
15. Pozzi A, Moberg PE, Miles LA, Wagner S, Soloway P, Gardner HA. Elevated matrix metalloproteinase and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci U S A. 2000;97:2202-2207.
16. Gardner H, Broberg A, Pozzi A, Laato M, Heino J. Absence of integrin alpha1beta1 in the mouse causes loss of feedback regulation of collagen synthesis in normal and wounded dermis. J Cell Sci. 1999;112(pt 3):263-272.
17. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002;90:520-530.
18. Rosenberg GA, Navratil M, Barone F, Feuerstein G. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab. 1996;16:360-366.
19. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90:251-262.
20. Dollery CM, Humphries SE, McClelland A, Latchman DS, McEwan JR. In vivo adenoviral gene transfer of TIPM-1 after vascular injury reduces neointimal formation. Ann N Y Acad Sci. 1999;30:742-743.
21. Uemura S, Matsushita H, Li W, Glassford AJ, Asagami T, Lee KH, Harrison DG, Tsao PS. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res. 2001;88:1291-1298.
22. D'Armiento FP, Bianchi A, de Nigris F, Capuzzi DM, D'Armiento MR, Crimi G, Abete P, Palinski W, Condorelli M, Napoli C. Age-related effects on atherogenesis and scavenger enzymes of intracranial and extracranial arteries in men without classic risk factors for atherosclerosis. Stroke. 2001;32:2472-2479.
23. Loftus JM, Goodall S, Crowther M, Jones L, Bell PRF, Naylor AR, Thompson MM. Increased MMP-9 activity in acute carotid plaques: therapeutic avenues to prevent stroke. Ann N Y Acad Sci. 1999;878:551-554.
24. Ryan ME, Ramamurthy NS, Sorsa T, Golub LM. MMP-mediated events in diabetes. Ann N Y Acad Sci. 1999;878:311-334.
25. Rothwell NJ, Luheshi GN. Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci. 2000;23:618-625.
26. Siwik DA, Chang DL, Colucci WS. Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res. 2000;86:1259-1265.
27. Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab. 1999;19:624-633.
28. Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke. 1998;29:1020-1030.
29. Hanemaaijer R, Koolwijk P, le Clercq L, de Vree WJ. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells: effects of tumor necrosis factor alpha, interleukin 1 and phorbol ester. J Biochem. 1993;296:803-809.
30. Jackson CJ, Nguyen M. Human microvascular endothelial cells differ from macrovascular endothelial cells in their expression of matrix metalloproteinases. Int J Biochem Cell Biol. 1997;29:1167-1177.
31. Kouwenhoven M, Carlstrom C, Ozenci V, Link H. Matrix metalloproteinase and cytokine profiles in monocytes over the course of stroke. J Clin Immunol. 2001;21:365-375.
32. Hirohata S, Kusachi S, Murakami M, Murakami T, Sano I, Watanabe T, Komatsubara I, Kondo J, Tsuji T. Time dependent alterations of serum matrix metalloproteinase-1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of acute myocardial infarction. Heart. 1997;78:278-284.
33. Montrucchio G, Lupia E, De Martino A, Silvestro L, Savu SR, Cacace G, De Filippi PG, Emanuelli G, Camussi G. Plasmin promotes an endothelium-dependent adhesion of neutrophils. Involvement of platelet activating factor and P-selectin. Circulation. 1996;93:2152-2160.
34. Murphy G, Knauper V. Relating matrix metalloproteinase structure to function: why the "hemopexin" domain? Matrix Biol. 1997;15:511-518.
35. Mandler RN, Dencoff JD, Midani F, Ford CC, Ahmed W, Rosenberg GA. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in cerebrospinal fluid differ in multiple sclerosis and Devic's neuromyelitis optica. Brain. 2001;124(pt 3):493-498.
36. Fasciglione GF, Marini S, D'Alessio S, Politi V, Coletta M. pH- and temperature-dependence of functional modulation in metalloproteinases. A comparison between neutrophil collagenase and gelatinases A and B. Biophys J. 2000;79:2138-2149.
37. Makowski GS, Ramsby ML. Binding of matrix metalloproteinase 9 to fibrin is mediated by amorphous calcium-phosphate. Inflammation. 1998;22:599-617.
38. Kolb SA, Lahrtz F, Paul R, Leppert D, Nadal D, Pfister HW, Fontana A. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in viral meningitis: upregulation of MMP-9 and TIMP-1 in cerebrospinal fluid. J Neuroimmunol. 1998;84:143-150.